Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2014
Multicenter phase II study evaluating docetaxel and cisplatin as neoadjuvant induction regimen prior to surgery or radiochemotherapy with docetaxel, followed by adjuvant docetaxel therapy in chemonaive patients with NSCLC stage II, IIIA and IIIB (TAX-AT 1.203 Trial)F Kocher, A Pircher, A Mohn-Staudner, et al.
Journal of Breath Research|August 31, 2012
Dependence of exhaled breath composition on exogenous factors, smoking habits and exposure to air pollutantsW Filipiak, V Ruzsanyi, P Mochalski, et al.
Experimental Hematology|September 16, 2000
Transplantation of IL-2-transduced murine bone marrow is associated with dose-dependent toxicityT Kühr, O Bechter, S Dirnhofer, et al.
Lung Cancer (Amsterdam, Netherlands)|March 21, 2014
Small steps of improvement in small-cell lung cancer (SCLC) within two decades: a comprehensive analysis of 484 patientsM Fiegl, A Pircher, C Waldthaler, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2009
Time-dependent association of total serum cholesterol and cancer incidence in a cohort of 172,210 men and women: a prospective 19-year follow-up studyA M Strasak, R M Pfeiffer, L J Brant, et al.
Leukemia Research|October 10, 1998
Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemiaW Hilbe, U Apfelbeck, M Fridrik, et al.
Leukemia & Lymphoma|March 26, 2002
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-CW Hilbe, T Kühr, U Apfelbeck, et al.
Leukemia Research|January 1, 1997
Interferon-alpha-2C and LD ara-C for the treatment of patients with CML: results of the Austrian multi-center phase II studyJ Thaler, W Hilbe, U Apfelbeck, et al.
Leukemia Research|March 7, 2003
A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML)T Kühr, S Burgstaller, U Apfelbeck, et al.
Pageof 5